How to use these clinical pharmacology questions

These nine single-best-answer cases cover common clinical pharmacology decisions: recognising an interaction, anticipating an adverse effect, interpreting drug monitoring and choosing an antidote. They are general practice questions, not a claim about the format of any particular examination. Check your course or the relevant examination body’s official syllabus for its scope and assessment format.

Each question has one best answer. The explanation identifies why it fits and why a tempting alternative does not. After the questions, a short written response shows how to make a clinical pharmacology answer specific enough to earn its marks.

1. Warfarin and metronidazole

This tests whether you can predict how an interacting medicine may change anticoagulant effect. In MySummaries, a browser question appears like this:

Question 11 mark

A patient taking stable warfarin is prescribed metronidazole. Their INR rises above the intended range. Which mechanism best explains the interaction?

Metronidazole inhibits the metabolism of warfarin, particularly through CYP2C9, and can increase anticoagulant effect and INR. Enzyme induction is the strongest distractor, but induction would generally increase metabolism and reduce warfarin exposure, not explain the rise. An interacting medicine warrants prompt INR and dose review with the anticoagulation team.

A single-best-answer question tests the direction and clinical consequence of a warfarin interaction.

The useful response is not just “interaction”: connect inhibition to increased exposure, a raised INR and bleeding risk, then state that monitoring and dose review are needed.

2. Lithium and ibuprofen

This tests how an analgesic can affect a medicine cleared by the kidneys.

Question 21 mark

A patient stable on lithium starts taking ibuprofen regularly for back pain. A week later, they develop nausea and a coarse tremor. What is the most likely pharmacological explanation?

NSAIDs such as ibuprofen can reduce renal perfusion and lithium clearance, increasing the risk of lithium toxicity. Increased hepatic metabolism is a tempting general interaction mechanism, but lithium is not metabolised by the liver. Assess for toxicity and arrange appropriate clinical review and lithium monitoring.

A lithium interaction question links renal clearance to emerging toxicity symptoms.

The strongest distractor is hepatic metabolism: many drug interactions involve enzymes, but lithium is eliminated largely unchanged by the kidneys. The route of elimination should guide your prediction.

3. Gentamicin monitoring

This tests how renal function and a drug level inform the next dose. Sampling times and target concentrations depend on the regimen and local protocol; the case asks for the safe principle, not a universal cut-off.

Question 31 mark

A patient receiving repeated gentamicin doses has a worsening estimated glomerular filtration rate and a higher-than-expected pre-dose concentration. What is the best next step?

Gentamicin is cleared mainly by the kidneys. Reduced renal function can prolong exposure, so a high pre-dose concentration calls for withholding or delaying the next dose and reviewing the dose interval and levels under the local protocol. Increasing the dose is the strongest distractor but risks further accumulation and toxicity.

A monitoring question tests the response to gentamicin accumulation as renal function worsens.

Do not memorise a level without its sampling time and dosing method. In practice, interpret the result against the prescribed regimen and local guidance.

4. Propranolol and asthma

This tests receptor selectivity and a predictable adverse effect.

Question 41 mark

A patient with asthma develops wheeze after starting propranolol for tremor. Which action best explains this adverse effect?

Propranolol blocks both β1 and β2 receptors. Blocking β2 receptors in bronchial smooth muscle can cause bronchoconstriction and may worsen asthma. Selective β1 blockade is the strongest distractor, but propranolol is non-selective.

A receptor-selectivity question links propranolol’s action to bronchospasm.

A strong explanation names both the receptor and the tissue effect; “it is contraindicated in asthma” does not show the mechanism.

5. Paracetamol overdose

This tests the role of the antidote rather than asking you to guess a treatment threshold. Management should follow local toxicology advice.

Question 51 mark

A patient presents after a potentially toxic paracetamol ingestion. Which statement best describes the action of N-acetylcysteine?

N-acetylcysteine supports glutathione-dependent detoxification of the reactive metabolite NAPQI. It is not an opioid antagonist, and inducing drug-metabolising enzymes would not be the intended protective mechanism. Assessment and treatment timing should follow the applicable toxicology protocol.

An antidote question checks the pharmacological basis of N-acetylcysteine treatment.

The key distinction is between removing the parent drug and preventing injury from its toxic metabolite. In an actual overdose, use urgent local poison-centre or emergency guidance rather than relying on a practice question.

6. Rifampicin and hormonal contraception

This tests enzyme induction and the risk of reduced exposure to another medicine.

Question 61 mark

A patient using an oral hormonal contraceptive is prescribed rifampicin. What interaction should be discussed?

Rifampicin is a potent enzyme inducer and can lower concentrations of some hormonal contraceptives, reducing effectiveness. Enzyme inhibition is the strongest distractor, but it predicts increased rather than reduced exposure. Discuss a suitable contraceptive strategy using current local guidance.

An enzyme-induction question tests the potential effect of rifampicin on contraceptive exposure.

A complete clinical response includes the possibility of contraceptive failure and a plan to discuss an alternative or additional method. Avoid naming a universally suitable method without considering the patient and local advice.

7. Digoxin and hypokalaemia

This tests how an electrolyte disturbance changes susceptibility to a medicine’s effects.

Question 71 mark

A patient taking digoxin develops hypokalaemia after an increase in loop-diuretic treatment. Why can this increase the risk of digoxin toxicity?

Potassium competes with digoxin at the sodium-potassium ATPase. Hypokalaemia can increase digoxin binding and sensitivity to its effects, raising toxicity risk. Increased hepatic breakdown is not the mechanism; assess the patient, electrolytes and digoxin treatment clinically.

A digoxin question links hypokalaemia to increased pharmacodynamic effect.

This is a pharmacodynamic interaction: the electrolyte changes the response at the drug’s target, rather than simply changing the drug concentration.

8. Simvastatin and clarithromycin

This tests a clinically important enzyme interaction and its consequence.

Question 81 mark

A patient taking simvastatin is prescribed clarithromycin. Which concern is most relevant?

Clarithromycin inhibits CYP3A4, which metabolises simvastatin. Increased simvastatin exposure can raise the risk of muscle toxicity, including myopathy. Enzyme induction is the strongest distractor, but it predicts lower exposure. Check current interaction guidance and the patient’s prescribed regimen.

A statin interaction question tests CYP3A4 inhibition and muscle toxicity risk.

When answering interaction questions, state the mechanism, the expected change in exposure and the adverse outcome that follows. Then identify the need for a medication review rather than assuming every interaction has the same management.

9. Naloxone and opioid toxicity

This tests receptor action and why monitoring must continue after the first response.

Question 91 mark

A patient with opioid-induced respiratory depression improves after naloxone. Why must they still be monitored?

Naloxone is an opioid-receptor antagonist, but its effect may be shorter than that of the opioid responsible. Respiratory depression can recur as naloxone wears off, so ongoing observation and further treatment may be needed. Irreversible receptor activation is the strongest distractor and is the opposite of naloxone’s action.

An antidote question tests the mismatch between naloxone and opioid duration of action.

A useful answer follows the timeline: reversal occurs, the antagonist may wear off first, and toxicity may return. That reasoning is more transferable than learning one drug pair in isolation.

Turn a missed mark into a written answer

Single-best-answer questions are efficient for checking one decision at a time. A short written response also tests whether you can link mechanism, consequence and action without relying on answer options. Here the prompt asks for a practical interaction plan; the candidate identifies most of the pharmacology but omits one counselling point.

Paper — Clinical Pharmacology — Drug interactions04:10
75%Clinical Pharmacology — Drug interactions — marked3/4 marks · 04:10 taken

A patient stable on warfarin starts metronidazole. Explain the likely interaction and outline a safe monitoring plan.

3/4

Metronidazole inhibits warfarin metabolism, so the INR may rise and bleeding risk increases. Arrange an INR check and review the warfarin dose with the anticoagulation team.

The mechanism, likely effect and monitoring plan are clear. The response does not tell the patient to seek advice promptly if they notice bleeding or other concerning symptoms.

Missed

Include a patient-facing safety instruction, such as seeking urgent clinical advice for signs of bleeding.

Model answerMetronidazole can inhibit warfarin metabolism and increase anticoagulant effect, causing the INR to rise. Contact the anticoagulation team promptly for an INR and dose review; do not make an unsupervised dose change. Explain that they should seek urgent clinical advice if bleeding occurs or they develop concerning symptoms. Continue monitoring as advised by the treating team.

A marked written response shows a strong interaction explanation with one patient-safety point missing.

That is a MySummaries paper, filled with clinical pharmacology material. Yours is written from your own notes. Start free

The missed mark is not another enzyme fact: it is communicating what the patient should do. When revising an interaction, practise the full sequence—mechanism, expected effect, monitoring or management, and patient advice.

Review what is costing marks

A topic-level review helps distinguish isolated slips from a repeated gap. These percentages are a study-platform view of practice performance, not an examination marking scheme. If “interactions” repeatedly costs marks, make a small set of retrieval prompts that ask for the perpetrator drug, the mechanism and the clinical consequence.

Where marks go missing
58%Drug interactions8×
67%Therapeutic drug monitoring6×
84%Antidotes and mechanisms5×
A practice dashboard ranks weaker clinical pharmacology sections and shows how often each has been tested.

A repeat error can be turned into one focused prompt rather than rereading an entire chapter. For example, if you twice miss the warfarin interaction mechanism, revise the mechanism and then retrieve the likely INR effect and monitoring action.

Remediation tray

You lost this mark twice: metronidazole is added to warfarin. What happens to the INR, and what monitoring action should follow?

Add cardDismiss
A remediation prompt targets a repeatedly missed warfarin interaction and its clinical response.

How MySummaries helps

Build a Clinical Pharmacology revision board from your own lecture slides, notes or PDFs. From that board, MySummaries can generate spaced-repetition cards and written practice papers marked against your material, so you can identify whether a missed answer reflects a forgotten interaction, a mechanism gap or an incomplete clinical plan. Open MySummaries.